Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Breast NeoplasmMetastasis

Interventions

DRUG

Eribulin

Trial Locations (11)

Zaragoza

Palma de Mallorca

Las Palmas de Gran Canaria

Salamanca

Barcelona

Badajoz

A Coruña

Pamplona

Oviedo

Madrid

Valencia

All Listed Sponsors

lead

MedSIR

OTHER

NCT02061085 - Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment | Biotech Hunter | Biotech Hunter